iStock photo illustration

A Danish life science company with a global research hub in Kendall Square will bring 200 jobs to Lexington and Watertown as it expands its Greater Boston presence.

Novo Nordisk announced Thursday it will hire researchers focused on data science, biology and chemistry research and RNAi R&D.

“The Boston area is the leading center of biopharmaceutical innovation in the U.S.,” Chief Scientific Officer Marcus Schindler said in a statement. “We are committing to further expansion and to having a major life sciences presence in the Boston area, to support pipeline expansion into new modalities, with the ultimate goal of delivering new innovative medicines to people living with chronic diseases.” 

The company will eliminate 100 positions in Seattle and Indianapolis as part of the consolidation to Greater Boston.

Novo Nordisk is converting 100,000 square feet into a new research center in Lexington, including 80,000 square feet that will be made available to other R&D groups.

A company spokesperson said the addresses of the Lexington and Watertown facilities were not immediately available. Novo Nordisk acquired Lexington-based Dicerna Pharmaceuticals, which has research facilities at 33 and 75 Hayden Ave., in 2021 for $3.3 billion.

Novo Nordisk’s global R&D business development headquarters is located at 255 Main St. in Kendall Square. The company acquired also Corvidia, a Waltham-based biotech, for $725 million in 2020.

The company has more than 54,000 global employees.